GeneDx Holdings Corp. (WGS)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$85.99-1.60%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · WGS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 96.6% |
| Our one-year growth estimate | diamond | 23.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 73.5 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 32 industry peers
WGS — earnings miss
Dated 2026-05-04
Results of Operations and Financial Condition. Financial Results for the Quarter Ended March 31, 2026 On May 4, 2026 , GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the quarter ended March 31, 2026 . Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.3, respectively, to this Current Report on Form 8-K. Consolidated Statements of Operation…
Why it matters: Meeting or beating guidance shows strong demand and good execution in the business.
Supportive ifQ3 revenue reported at $122 million or more.
Worry ifQ3 revenue reported below $122 million.
Why it matters: Growth in these areas is crucial for the company's overall revenue health.
Supportive ifExome and genome revenue growth reported above 15% year over year.
Worry ifExome and genome revenue growth reported below 5% year over year.
Why it matters: New coverage would help more patients access testing and boost revenue.
Supportive ifNew state Medicaid programs will cover exome or genome testing.
Worry ifNo new Medicaid coverage news in the next quarter.
Why it matters: Volume growth below expectations may mean weaker demand.
Worry ifExome and genome test volume growth below 30% compared to last year.
Less concerning ifExome and genome test volume growth reported at 30% or higher.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$288 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $718 loss on $10,000 · 7.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,940 loss on $10,000 · 79.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Hitting this goal would show progress to making money and support management's focus.
Supportive ifAdjusted net income reported at or above $2 million.
Worry ifNet income was less than $2 million.
Why it matters: This goal matters for the company's financial recovery. It also affects investor trust.
Supportive ifThe company reports adjusted net income for the quarter. This shows improvement.
Worry ifThere are continued losses in adjusted net income. This shows ongoing financial struggles.